1.80
Mainz Biomed N V stock is traded at $1.80, with a volume of 129.77K.
It is up +1.69% in the last 24 hours and down -4.76% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
See More
Previous Close:
$1.77
Open:
$1.77
24h Volume:
129.77K
Relative Volume:
0.85
Market Cap:
$8.24M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-1.0976
EPS:
-1.64
Net Cash Flow:
$-23.84M
1W Performance:
+20.81%
1M Performance:
-4.76%
6M Performance:
-70.00%
1Y Performance:
-86.57%
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MYNZ
Mainz Biomed N V
|
1.80 | 8.10M | 895.50K | -26.30M | -23.84M | -1.64 |
![]()
TMO
Thermo Fisher Scientific Inc
|
487.54 | 184.66B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
209.01 | 151.04B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
637.86 | 52.07B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
118.15 | 33.86B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
192.54 | 32.49B | 15.70B | 1.24B | 2.01B | 6.91 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-25 | Initiated | Maxim Group | Buy |
Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
What’s next for Mainz Biomed N.V. stockJuly 2025 Recap & Weekly Breakout Watchlists - thegnnews.com
Can Mainz Biomed N.V. navigate macro headwindsRate Cut & Target Return Focused Stock Picks - thegnnews.com
Why Mainz Biomed N.V. stock attracts strong analyst attention2025 Retail Activity & Community Consensus Trade Alerts - beatles.ru
What are Mainz Biomed N.V.’s recent SEC filings showing2025 Market Sentiment & Risk Controlled Swing Alerts - sundaytimes.kr
Is Mainz Biomed N.V. a speculative investmentJuly 2025 PreEarnings & AI Powered Buy/Sell Recommendations - newsyoung.net
Mainz Biomed Wins Swiss Regulatory Approval for Colorectal Cancer Screening Test - MarketScreener
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval - Investing.com India
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval By Investing.com - Investing.com South Africa
Mainz Biomed N.V. Receives Swiss Regulatory Approval to Market ColoAlert - MarketScreener
Is Mainz Biomed N.V. stock reversal real or fakeShort-Term Profit Alert With Entry Forecast - Newser
Mainz Biomed Secures $3 Million Through Securities Purchase Agreement - The Globe and Mail
Mainz Biomed Secures $3 Million in Funding Through Securities Purchase Agreement - AInvest
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit - MarketScreener
Mainz Biomed raises $3M in follow-on offering. - AInvest
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants - 富途牛牛
Mainz Biomed Raises $3M in Follow-On Offering, Expects to Close on August 5 - AInvest
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
What is Mainz Biomed N.V. company’s growth strategySuperior portfolio returns - Jammu Links News
Should I hold or sell Mainz Biomed N.V. stock in 2025Achieve rapid capital gains with smart investing - Jammu Links News
Is Mainz Biomed N.V. stock overvalued or undervaluedGet alerts on high-potential market moves - Jammu Links News
What institutional investors are buying Mainz Biomed N.V. stockGet real-time updates on market movers - Jammu Links News
What is the risk reward ratio of investing in Mainz Biomed N.V. stockSkyrocketing returns - Jammu Links News
Why is Mainz Biomed N.V. stock attracting strong analyst attentionBuild wealth steadily with proven investment strategies - Jammu Links News
How does Mainz Biomed N.V. compare to its industry peersGet alerts on the hottest market movers - Jammu Links News
What is the dividend policy of Mainz Biomed N.V. stockRapid return acceleration - Jammu Links News
Does Mainz Biomed N.V. stock perform well during market downturnsTremendous return on equity - Jammu Links News
How strong is Mainz Biomed N.V. company’s balance sheetUnprecedented growth rates - Jammu Links News
What catalysts could drive Mainz Biomed N.V. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
How many analysts rate Mainz Biomed N.V. as a “Buy”Advanced Screener Planner For 2025 - Jammu Links News
Mainz Biomed Announces Sale of 1.47 Million Ordinary Units to Bolster Financial Position and Support Growth Initiatives - AInvest
What are Mainz Biomed N.V. company’s key revenue driversDaily Trading Outlook With Proven Results - Jammu Links News
Chartists See Breakout Potential in Mainz Biomed N.V.Real Trader Watchlist of Hot Stocks Released - metal.it
What are the technical indicators suggesting about Mainz Biomed N.V.Stay ahead with advanced stock screening tools - Jammu Links News
What institutions are buying Mainz Biomed N.V. stock nowFree Stock Market Beginners Guide - metal.it
Mainz Biomed N.V. Stock Analysis and ForecastStrong return on assets - Jammu Links News
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):